Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

SML2852

Sigma-Aldrich

Capadenoson

≥98% (HPLC)

Synonyme(s) :

2-Amino-6-[[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl]sulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, 2-Amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile, BAY 68-4986, BAY-68-4986, BAY68-4986

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C25H18ClN5O2S2
Numéro CAS:
544417-40-5
Poids moléculaire :
520.03
Numéro MDL:
MFCD09954113
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

N#CC1=C(C2=CC=C(OCCO)C=C2)C(C#N)=C(N)N=C1SCC3=CSC(C4=CC=C(Cl)C=C4)=N3

InChI

1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)

Clé InChI

CITWCLNVRIKQAF-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPγS binding EC50/Emax = 0.1 nM/74% vs. 0.3 nM/100% with CCPA; human cortex membranes) that exerts additional biased A2BAR agonism toward cAMP signal transduction (pEC50 = 8.94/cAMP, 6.20/Ca+2, 6.12/pERK, 5.03/IP1), while exhibiting weak A2A & A3 potency. Capadenoson offers cardioprotection efficacy in an ischemia-reperfusion injury rat model in vivo (25/28% infarct size reduction with 0.1/0.3 mg/kg iv.) without the risk of a full atrioventricular (AV) block (isolated perfused rat heart rate = 100% up to 10 nM, 90% at ≥10 μM) seen with the full A1 agonist CCPA.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Isaac R Bailey et al.
The Journal of pharmacology and experimental therapeutics, 362(3), 424-430 (2017-06-28)
Cardiac arrest is a leading cause of death in the United States, and, currently, therapeutic hypothermia, now called targeted temperature management (TTM), is the only recent treatment modality proven to increase survival rates and reduce morbidity for this condition. Shivering
Daniel Meibom et al.
ChemMedChem, 12(10), 728-737 (2017-05-11)
Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1 Rs) has been shown to inhibit myocardial pathologies associated
Barbara E Albrecht-Küpper et al.
Purinergic signalling, 8(Suppl 1), 91-99 (2011-11-15)
Adenosine, a purine nucleoside, is present in all cells in tightly regulated concentrations. It has many different physiological effects in the whole body and in the heart. Adenosine activates four G protein-coupled receptors A1, A2a, A2b, and A3. Activation of
Jo-Anne Baltos et al.
Biochemical pharmacology, 135, 79-89 (2017-03-28)
The adenosine A2B receptor (A2BAR) has been identified as an important therapeutic target in cardiovascular disease, however in vitro and in vivo targeting has been limited by the paucity of pharmacological tools, particularly potent agonists. Interestingly, 2-((6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)-2-pyridinyl)thio)acetamide (BAY60-6583), a potent
Samantha L Cooper et al.
British journal of pharmacology, 177(2), 346-359 (2019-10-10)
Adenosine is a local mediator that regulates physiological and pathological processes via activation of four GPCRs (A1 , A2A , A2B , and A3 ). We have investigated the effect of two A1 -receptor-selective agonists and the novel A1 -receptor
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique